Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EHP-101 (VCE-004.8) is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. EHP-101 attenuates adipogenesis and prevents diet-induced obesity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 109.00 | |
5 mg | In stock | $ 239.00 | |
10 mg | In stock | $ 397.00 | |
25 mg | In stock | $ 652.00 | |
50 mg | In stock | $ 913.00 | |
100 mg | In stock | $ 1,230.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 263.00 |
Description | EHP-101 (VCE-004.8) is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. EHP-101 attenuates adipogenesis and prevents diet-induced obesity. |
In vivo | In HFD mice, VCE-004.8 (injection; 20?mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume, and plasma triglycerides levels. VCE-004.8 can also significantly improve glucose tolerance, reduce leptin levels (a sign of obesity) and increase the levels of adiponectin and glucagon (GLP-1 and GIP) [1]. |
Synonyms | VCE-004.8 |
Molecular Weight | 433.58 |
Formula | C28H35NO3 |
CAS No. | 1818428-24-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 49 mg/mL (113.01 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EHP-101 1818428-24-8 Chromatin/Epigenetic DNA Damage/DNA Repair GPCR/G Protein Metabolism PPAR Cannabinoid Receptor HIF/HIF Prolyl-Hydroxylase Peroxisome proliferator-activated receptors VCE-004.8 EHP101 HIF-PH Hypoxia-inducible factors inhibit VCE-?004.8 Inhibitor HIFs EHP 101 VCE-004.8 inhibitor